Komori
KYORIN Pharmaceutical (4569) · RiskRestated

Uncertainty over Recovering R&D Investment and Launching Pharmaceuticals

First written in FY2017. 3 of 4 entries say "Restated". Latest entry: FY2024.

4entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY20242017: 120172018: 120182019: 120192020: 020202021: 020212022: 020222023: 020232024: 12024
Same theme, other companies
Uncertainty over Prolonged or Discontinued Drug Development Pipelines and CommercializationA theme 69 companies write about · 85 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2022: 20 of 40 companies on the "Worse" side.

28 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 69 companies compared. The sentences above are computed from all 69.
Full recordFilings, disclosures and news, newest first
  1. FY2024RestatedAnnual report

    「The development of prescription drugs requires substantial R&D investment and a long period of time, and the probability that a development candidate can be brought to market as a pharmaceutical is by no means high. If development is delayed or discontinued because safety issues arise with a development candidate or its expected efficacy cannot be confirmed, this could materially affect the operating performance and financial condition of the Company Group.」

    The disclosure continues to identify the long-term nature of R&D investment and the risks of delays or discontinuation arising from the safety and efficacy of development candidates.
  2. FY2019RestatedAnnual report

    「The development of prescription pharmaceuticals requires substantial R&D investment and a long period of time, while the probability of discovering highly novel compounds and bringing them to market as pharmaceuticals is by no means high.」

    The recovery of R&D investment and uncertainty over pharmaceutical launches continue to be described as risks.
  3. FY2018RestatedAnnual report

    「The development of prescription pharmaceuticals requires substantial R&D investment and a long period of time, while the probability of discovering highly novel compounds and bringing them to market as pharmaceuticals is by no means high.」

    The recovery of R&D investment and uncertainty over product launches continue to be described as risks.
  4. FY2017First statedAnnual report

    「The development of prescription pharmaceuticals requires substantial R&D investment and a long period of time, while the probability of discovering highly novel compounds and bringing them to market as pharmaceuticals is by no means high.」

    The Company discloses the risk that substantial, long-term R&D investment may not result in a product launch.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Uncertainty over Recovering R&D Investment and Launching Pharmaceuticals | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori